Management strategy in aplastic anemia patients with HBV infection following intensive immunosuppressive therapy in Chinese cohort: prophylactic antiviral therapy may not be necessary with close monitoring | Synapse
April 15, 2026Open Access
Management strategy in aplastic anemia patients with HBV infection following intensive immunosuppressive therapy in Chinese cohort: prophylactic antiviral therapy may not be necessary with close monitoring
Key Points
To evaluate the necessity of prophylactic antiviral therapy in aplastic anemia patients with chronic HBV infection receiving immunosuppressive therapy.
Evaluated outcomes of aplastic anemia patients with chronic and resolved HBV infections.
Implemented stringent surveillance methods for patients with resolved HBV infections.
Prophylactic antiviral therapy is necessary for patients with chronic HBV infection during immunosuppressive therapy.
For patients with resolved HBV infection, close monitoring is sufficient without prophylactic antiviral drugs.
Abstract
Overall, AA patients with chronic HBV infection need to receive prophylactic antiviral drugs during IST, while stringent surveillance methods are necessary for patients with resolved HBV infection.